Volume 34, Issue 4 , Pages 445-453, April 1995
Lithium in Hospitalized Aggressive Children with Conduct Disorder: A Double-Blind and Placebo-Controlled Study
ABSTRACT
Objective
To assess critically the efficacy and safety of lithium and replicate earlier findings in a larger sample of aggressive children with conduct disorder and to assess the utility of the Profile of Mood States (POMS) in this population.
Method
Children hospitalized for treatment-refractory severe aggressiveness and explosiveness and with diagnosed conduct disorder were subjects in this double-blind, placebo-controlled clinical trial. After a 2-week placebo baseline period, children were randomly assigned to lithium or placebo treatment for 6 weeks followed by 2 weeks of placebo. The main outcome measures were the Global Clinical Judgments (Consensus) Scale, Children's Psychiatric Rating Scale, Conners Teacher Questionnaire, Parent-Teacher Questionnaire, and the POMS.
Results
Fifty children (mean age 9.4 years) completed this study. The mean optimal dally dose of lithium was 1,248 mg and the mean serum level was 1.12 mEq/L. Lithium was superior to placebo, although the effects on some measures were more modest than in a previous study.
Conclusions
Lithium appears to be an effective treatment for some severely aggressive children with conduct disorder. Although the POMS appeared to be reliable, it did not detect any response to lithium.
Key Words: lithium , aggressiveness , explosiveness , conduct disorder
No full text is available. To read the body of this article, please view the PDF online.
To access this article, please choose from the options below
This research was supported in part by USPHS grants MH-40177 (Dr. Campbell) and MH-18915 (Drs. Campbell, Kafantaris, and Silva) from the NIMH; the Hirschell and Deanna E. Levine Foundation, The Marion O. and Maximilian E. Hoffman Foundation, Inc., and The Beatrice and Samuel A. Seaver Foundation. The authors thank the New York Health and Hospitals Corporation and the Bellevue Hospital Center for their cooperation; Reid-Rowell, Inc., for supplying lithium carbonate (Lithonate) and matching placebo capsules; Camille Petty, R.N., the Nursing Staff on 21 South, and the Teachers of Public School 106 for their participation.
PII: S0890-8567(09)63730-8
doi:10.1097/00004583-199504000-00011
© 1995 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 34, Issue 4 , Pages 445-453, April 1995
